William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.
William Eward, MD, DVM
Advertisement
Articles by William Eward, MD, DVM
William Eward, MD, DVM, discusses the approval of pexidartinib to treat patients with tenosynovial giant cell tumor.
Advertisement
Latest Updated Articles
Dr. Eward on FDA Approval of Pexidartinib in TGCTOctober 30th 2019
Dr. Eward on the Unmet Need for Novel Agents for TGCT and SarcomaFebruary 13th 2020
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
3
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5